Navigation Links
Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
Date:7/27/2009

THOUSAND OAKS, Calif. and LONDON, July 27 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and GlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico once the product is approved in these countries. Amgen will commercialize the drug for PMO and oncology in the United States (U.S.) and Canada and for all oncology indications in Europe and specified markets.

GlaxoSmithKline will register and commercialize denosumab for all indications in countries where Amgen does not currently have a commercial presence, including China, Brazil, India and South Korea. The structure of the collaboration allows Amgen the option of an expanded role in commercialization in both Europe and certain emerging markets in the future.

Financial terms of the partnership include an initial payment and near-term commercial milestones to Amgen totaling $120 million, and ongoing royalties. In Europe, Amgen and GlaxoSmithKline will share profits after accounting for expenses associated with the partnership. In emerging markets, GlaxoSmithKline will be responsible for all commercialization expenses and purchase denosumab from Amgen to meet demand.

The companies' combined commercialization activities will expand access to denosumab, once approved, to patients worldwide who are afflicted by osteoporosis and other bone loss conditions.

"Our collaboration with GlaxoSmithKline will help Amgen bring the promise of denosumab to patients in Europe and other parts of the world more effectively than if we commercialized the drug globally on our own," said Amgen CEO Kevin Sharer. "Amgen and GlaxoSmithKline
'/>"/>

SOURCE Amgen; GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
4. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
9. Call for Applications: The Amgen Award for Science Teaching Excellence
10. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... July 1, 2015 R-Japan Co.,Ltd. obtained the license ... of Regenerative Medicine from the Ministry of Health, Labour and ... 2015. The fact that R- Japan ... the auditing from Pharmaceuticals and Medical Devices Agency (PMDA) on ... it to provide stem cell manufacturing service to medical institutions. ...
(Date:6/30/2015)... CALGARY , June 30, 2015 /PRNewswire/ - ... ("Shareholders") of common shares of Resverlogix have approved ... to Eastern Capital Limited of 5,600,000 units at ... Private Placement"), each unit being comprised of one ... for aggregate proceeds of approximately CAD$15 million; and ...
(Date:6/30/2015)... June 30, 2015  NASA astronaut Kjell Lindgren , ... on his first mission to the International Space Station ... to 9 a.m. EDT Tuesday, July 7. Lindgren ... City, Russia . The interviews will be ... highlighting his mission training. To schedule an interview, ...
(Date:6/30/2015)... , June 30, 2015  Today, Americord Registry, one ... announced Andrew Horne , a partner at Kirkland & ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... Americord,s Advisory Board," says Martin Smithmyer , CEO of ... his legal career that will assist Americord,s growth and vision." ...
Breaking Biology Technology:R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2Americord Registry Announces Andrew Horne as Advisory Board Member 2
... campaign season, and you've been poked and prodded by television ... John Kerry drank a beer at your neighborhood bar and ... Dick Cheney was spotted more in Wisconsin in 2004 than ... years. John Edwards has been in the state so often ...
... studies stem cells in his Primate Center lab. Photo ... Wis. James Thomson avoided talking ... the presidential election, explaining instead the science behind his ... on the University of Wisconsin-Madison campus since his 1998 ...
... Silicon Graphics Inc. Chippewa Valley, Wis. — ... in about 129 days, and it was the company's Chippewa ... the completion of the $50 million project for NASA ... space shuttle that crashed last year, runs on SGIs ...
Cached Biology Technology:Twenty ways you can tell this campaign has finally pushed you over the edge 2James Thomson plans to stay in Madison to study genesis of stem cells 2James Thomson plans to stay in Madison to study genesis of stem cells 3SGIs Wisconsin branch builds fastest supercomputer yet in four months 2
(Date:6/11/2015)... 2015 Daon, a global leader in ... IdentityX Mobile Authentication Platform v4.0 has been FIDO ... an industry consortium launched in 2013 to revolutionize ... authentication.  In order to receive certification, a company,s ... of tests that measure compliance and ensure interoperability ...
(Date:6/9/2015)... , June 09, 2015 Research ... addition of the "Gesture Recognition & Touchless ... (Consumer Electronics, Automotive, & Others), Product (Biometric & ... to 2020" report to their offering. ... market is expected to reach $ 23.55 Billion ...
(Date:6/5/2015)... Md. , June 5, 2015  Intrexon Corporation ... biology, today announced that it has determined the final ... all of its 17,830,305 shares of ZIOPHARM Oncology, Inc. ... about June 12, 2015, the distribution date, as a ... and on warrants to purchase shares of Intrexon common ...
Breaking Biology News(10 mins):Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 2Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 3Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 4
... 3, 2009 -- Despite the striking aromatic differences between ... nose,s neural circuitry suggests a haphazard patchwork where the ... not to be neighbors. Inexplicably, this seemingly random ... with cells that process the same scent located in ...
... the Swiss National Center of Competence in Research in ... to predict how breast cancer patients respond to chemotherapy, ... the future. In an article, ,A stroma-related gene signature ... published in Nature Medicine , Dr Pierre Farmer ...
... automobile, even during an economic downturn. Every day, hundreds ... remote places, to commute, and to reach the supermarket. ... trillions of dollars and millions of worker-hours. Miklos Szilagyi ... an apparent waste of resources, a serious producer of ...
Cached Biology News:Neural mapping paints a haphazard picture of odor receptors 2Stroma genomic signature predicts resistance to anthracyclin-based chemotherapy in breast cancer 2Stroma genomic signature predicts resistance to anthracyclin-based chemotherapy in breast cancer 3Defectors take the car, cooperators go by bus 2
... Lines ,High Quality, Functionally-Validated, Ion Channel Cell ... for having a critical role in nerve ... key function in pain, CNS and the ... been investigated in therapeutic areas, such as ...
Mouse polyclonal antibody raised against a partial recombinant CD320. NCBI Entrez Gene ID = 51293...
Mouse monoclonal antibody raised against a partial recombinant CHD8. NCBI Entrez Gene ID = CHD8...
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Biology Products: